Dinotefuran + Permethrin + Pyriproxyfen

Verify with FDA CVM →

14 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

DinotefuranPermethrinPyriproxyfen

Administration Routes

TopicalUnknown

Species Affected

Dog 14

Most Affected Breeds

Crossbred Canine/dog 2
Boxer (German Boxer) 2
Shepherd Dog - Australian 2
Siberian Husky 1
Pointing Dog - German Short-haired 1
Sheepdog - Shetland 1
Chihuahua 1
Bulldog 1
Dog (unknown) 1
Retriever - Labrador 1

Most Reported Reactions

Pruritus 3
Application site irritation 3
Application site erythema 2
Application site reddening 2
Emesis 2
Lack of efficacy (endoparasite) - heartworm 2
Application site pustule 1
Anxiety 1
Restlessness 1
Sleep disturbance NOS 1
Erythema (for urticaria see Immune SOC) 1
Application site twitching 1

Outcome Breakdown

Recovered/Normal
8 (57.1%)
Ongoing
3 (21.4%)
Outcome Unknown
2 (14.3%)
Recovered with Sequela
1 (7.1%)

Data Summary

Metric Value
Total adverse event reports 14
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dinotefuran + Permethrin + Pyriproxyfen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 14 adverse event reports referencing Dinotefuran + Permethrin + Pyriproxyfen, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Dinotefuran, Permethrin, Pyriproxyfen. Reported administration routes include Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dinotefuran + Permethrin + Pyriproxyfen reports are Dog (14 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (2), Boxer (German Boxer) (2), Shepherd Dog - Australian (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dinotefuran + Permethrin + Pyriproxyfen are Pruritus (3), Application site irritation (3), Application site erythema (2), Application site reddening (2). Of the 14 reports with a coded outcome, Recovered/Normal is the leading category at 57.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dinotefuran + Permethrin + Pyriproxyfen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial